GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox

December 19, 2023

https://www.globenewswire.com/news-release/2023/12/19/2798597/0/en/GeoVax-Expands-Rights-Under-NIH-COVID-19-License-to-Include-Mpox-and-Smallpox.html

ATLANTA, GA, Dec. 19, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – GeoVax Labs, Inc. (Nasdaq:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it has amended a previously executed Patent and Biological Materials License Agreement (the “License Agreement”) with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), in support of GeoVax’s development of a vaccine against SARS-CoV-2 (COVID-19). The amendment expands GeoVax’s commercial license to include Mpox and smallpox as additional indications.

Read more at globenewswire.com

Related news for (GOVX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.